Show simple item record

dc.contributor.authorOsuna Prieto, Francisco Javier 
dc.contributor.authorAcosta, Francisco M.
dc.contributor.authorPérez de Arrilucea Le Floc'h, Unai A.
dc.contributor.authorRiquelme Gallego, Blanca 
dc.contributor.authorMerchán Ramírez, Elisa 
dc.contributor.authorXu, Huiwen 
dc.contributor.authorCruz Márquez, Juan Carlos De La 
dc.contributor.authorAmaro Gahete, Francisco José 
dc.contributor.authorLlamas Elvira, José Manuel 
dc.contributor.authorTriviño Ibáñez, Eva María
dc.contributor.authorSegura Carretero, Antonio 
dc.contributor.authorRuiz Ruiz, Jonatan
dc.identifier.citationFrancisco J. Osuna-Prieto... [et al.] (2022) Dihydrocapsiate does not increase energy expenditure nor fat oxidation during aerobic exercise in men with overweight/obesity: a randomized, tripleblinded, placebo-controlled, crossover trial, Journal of the International Society of Sports Nutrition, 19:1, 417-436, DOI: [10.1080/15502783.2022.2099757]es_ES
dc.description.abstractBackground: Prior evidence suggests that capsinoids ingestion may increase resting energy expenditure (EE) and fat oxidation (FATox), yet whether they can modulate those parameters during exercise conditions remains poorly understood. We hypothesized that dihydrocapsiate (DHC) ingestion would increase EE and specifically FATox during an acute bout of aerobic exercise at FATmax intensity (the intensity that elicits maximal fat oxidation during exercise [MFO]) in men with overweight/ obesity. Since FATmax and MFO during aerobic exercise appear to be indicators of metabolic flexibility, whether DHC has an impact on FATox in this type of population is of clinical interest. Methods: A total of 24 sedentary men (age = 40.2 ± 9.2 years-old; body mass index = 31.6 ± 4.5 kg/m2 [n = 11 overweight, n = 13 obese]) participated in this randomized, triple-blinded, placebocontrolled, crossover trial (registered under Identifier no. NCT05156697). On the first day, participants underwent a submaximal exercise test on a cycle ergometer to determine their MFO and FATmax intensity during exercise. After 72 hours had elapsed, the participants returned on 2 further days (≥ 72 hours apart) and performed a 60 min steady-state exercise bout (i.e. cycling at their FATmax, constant intensity) after ingesting either 12 mg of DHC or placebo; these conditions were randomized. Respiratory gas exchange was monitored by indirect calorimetry. Serum marker concentrations (i.e. glucose, triglycerides, non-esterified fatty acids (NEFAs), skin temperature, thermal perception, heart rate, and perceived fatigue) were assessed. Results: There were no significant differences (P > 0.05) between DHC and placebo conditions in the EE and FATox during exercise. Similarly, no significant changes were observed in glucose, triglycerides, or NEFAs serum levels, neither in the skin temperature nor thermal perception across conditions. Heart rate and perceived fatigue did not differ between conditions. Conclusions: DHC supplementation does not affect energy metabolism during exercise in men with overweight/obesity.es_ES
dc.description.sponsorshipSpanish Junta de Andalucia via Consejeria de Conocimiento, Investigacion y Universidades, Proyectos I+D+i del Programa Operativo del Fondo Europeo de Desarrollo Regional (FEDER 2018) B.CTS.377.UGR18es_ES
dc.description.sponsorshipSpanish Government PTA 12264-I FPU16/02828 FPU16/05159es_ES
dc.publisherTaylor & Francises_ES
dc.rightsAtribución 4.0 Internacional*
dc.subjectObesity es_ES
dc.subjectMetabolism es_ES
dc.titleDihydrocapsiate does not increase energy expenditure nor fat oxidation during aerobic exercise in men with overweight/ obesity: a randomized, triple-blinded, placebo-controlled, crossover triales_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional